• Users Online: 5160
  • Home
  • Print this page
  • Email this page
INVITED REVIEW
Year : 2015  |  Volume : 10  |  Issue : 8  |  Page : 1181-1185

Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease


1 Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown NSW, Australia
2 Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown NSW; Molecular Medicine Research Group, University of Western Sydney, NSW, Australia
3 Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown NSW; National Institute of Complementary Medicine, University of Western Sydney; Molecular Medicine Research Group, University of Western Sydney, NSW, Australia

Correspondence Address:
Gerald Münch
Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown NSW; National Institute of Complementary Medicine, University of Western Sydney; Molecular Medicine Research Group, University of Western Sydney, NSW
Australia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1673-5374.162686

Rights and Permissions

Alzheimer's disease is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Current treatments for Alzheimer's disease primarily focus on enhancement of cholinergic transmission. However, these treatments are only symptomatic, and no disease-modifying drug is available for Alzheimer's disease patients. This review will provide an overview of the proven antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects of curcumin and apigenin and discuss the potential of these compounds for Alzheimer's disease prevention and treatment. We suggest that these compounds might delay the onset of Alzheimer's disease or slow down its progression, and they should enter clinical trials as soon as possible.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4418    
    Printed51    
    Emailed1    
    PDF Downloaded1135    
    Comments [Add]    
    Cited by others 50    

Recommend this journal